KIF1A is a plus-end-directed kinesin motor protein essential for anterograde axonal transport of synaptic vesicle precursors (SVPs) and dense core vesicles (DCVs) 1. The motor function is regulated through calcium-dependent interactions with CALM1, which increases vesicle motility, and through scaffolding protein interactions with PPFIA2 and TANC2 that recruit DCVs to synaptic sites [UniProt]. KIF1A specifically recognizes phosphatidylinositol 3,5-bisphosphate on precursor vesicles via coincident detection with active ARL8, directing cotransport of both synaptic vesicle and active zone proteins to developing presynapses 1. Pathogenic KIF1A variants cause multiple neurodegenerative disorders. Mutations in KIF1A represent a significant portion of hereditary spastic paraplegia (HSP) cases, particularly SPG30, affecting long central nervous system axons with maximal corticospinal tract degeneration 23. KIF1A also associates with hereditary sensory and autonomic neuropathy type 2 (HSAN2) and amyotrophic lateral sclerosis (ALS), where variants predominantly in the C-terminal cargo-binding region enhance SVP binding 4. KIF1A-associated neurological disorder (KAND) represents a severe neurodegenerative condition with heterozygous de novo missense variants, recently showing therapeutic responsiveness to allele-specific antisense oligonucleotide treatment 5. Beyond neurological disease, KIF1A unexpectedly promotes neuroendocrine differentiation in prostate cancer through OGT-mediated O-GlcNAcylation 6.